- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Treatment of Neuropathic Pain: A Close Look at a New Meta-Analysis
For the often treatment-resistant pain of neuropathic conditions, the meta-analysis includes updated evidence for both pharmacologic and neuromodulatory interventions.
Neuropathic pain, caused by a lesion or disease of the somatosensory nervous system, remains one of the most difficult forms of chronic pain to manage. Effective treatment requires careful diagnosis and a biopsychosocial approach, along with evidence-based recommendations that account for efficacy, safety, and patient preferences.1 In response to advances in pharmacologic therapies, neuromodulation techniques, and methods to evaluate evidence, the Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain has updated its clinical guideline. The recommendations are based on a systematic review and meta-analysis of randomized controlled trials and provide new estimates of treatment efficacy, safety, and tolerability.
The at-a-glance slide show above summarizes the key findings of the analysis for office-based primary care clinicians with spare time at a premium and may help guide individualized patient care.
